

nFC 1 0 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Tytan Medical Corp. c/o Mr. William Hsieh 1-3 F, No.2, 1 Lane, Juang Shing Road, Sec.1, WU GU 248, Taipei Hsien, R.O.C. CHINA (TAIWAN) 248

Re: K033025

Trade Name: TYTAN Professional/Economy Series Sphygmomanometer, No 700/710

Regulation Number: 21 CFR 870.1130

Regulation Name: Non-invasive Blood Pressure Measurement System

Regulatory Class: Class II (two)

Product Code: DXN

Dated: September 20, 2003 Received: September 26, 2003

Dear Mr. Hsieh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 – Mr. William Hsieh

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4648. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Dimoston

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

TYTAN MEDICAL CORP.

No2, 1st Lane, Jung Shing Road Section 1, Wu Gu, Taipei, 248, Taiwan R.O.C.

Telephone: 886-2-8988-3828

Fax: 886-2-8981-2254

Email: service@tytan.com.tw

3. Indications for use statement

Applicant: TYTAN Medical Corp.
510(k) Number (if known):TBA
Device Name: Tytan Professional series No. 710 / Economy series No. 700
• Indications for use:
The device is a noninvasive blood pressure measurement system intended to measure the systolic and diastolic blood pressures at home by using a non-invasive technique in which an inflatable cuff is wrapped around the arm. The cuff circumference ranges are 3 1/2" to 5 1/4", 3 3/4" to 7 1/2", 7" to 10 3/4", 10 3/4" to 15 3/4", and 13 1/3" to 19 1/2". The patient population targets are newborn, infant, child, adult.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE)
Concurrence of CDRH, office of Device Evaluation (ODE) (Division Sign-Off) Division of Cardiovascular Devices 510(k) Number 133025
Prescription Use OR Over—The—Counter—Use_X
(Per 21 CFR 801.109) (Optional Format 1-2-96)